11-OH-THC11-Hydroxy-Δ9-tetrahydrocannabinol
Active THC metabolite formed by the body; its levels are much higher after ingestion than after inhalation.
C₂₁H₃₀O₃
CAS 36557-05-8
- Family
- Metabolite
- Molar mass
- 330.47 g/mol
Updated on
In plain terms
11-OH-THC is the molecule the body, mainly the liver, makes from THC, and it also acts on the brain. After an ingested product, its blood level is close to that of THC, whereas it reaches only about 10% of it after inhalation.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to 11-OH-THC: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 11-OH-THC.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Partial agonistEC50 = 11 nM · human66 out of 100
Zagzoog A et al. 2022, Front Pharmacol (new tab) · cAMP inhibition, human CB1 in CHO-K1 cells; efficacy 28% (Δ9-THC 70%); Ki estimated at 0.37 nM with partial displacement (~30%) of [3H]CP55,940
Pharmacology
11-Hydroxy-Δ9-tetrahydrocannabinol is the active metabolite of Δ9-THC, described by Huestis (2007) as equipotent. Nilsson et al. identified it in 1970 as a major THC metabolite in a rabbit liver fraction; it arises from hydroxylation of the 11-methyl group, attributed mainly to CYP2C9. Its share depends on the route: about 10% of THC concentrations after inhalation, similar concentrations after oral intake. Lemberger et al. (1973) injected 1 mg intravenously into nine occasional users: marked tachycardia and a "high" appeared within 3 to 5 minutes, against a peak delayed by 10 to 20 minutes with 1 mg of Δ9-THC, and the effect tracked concentrations of the unchanged metabolite. In vitro, it behaved as a partial agonist of human CB1 (EC50 11 nM, efficacy 28% versus 70% for Δ9-THC; Zagzoog et al. 2022). It is then metabolised by CYP3A, UGT2B7 and CYP2C9, and oxidised to THC-COOH, which is inactive.
Key sources.
- Nilsson IM, Agurell S, Nilsson JL, Ohlsson A, Sandberg F, Wahlqvist M. Delta-1-tetrahydrocannabinol: structure of a major metabolite. Science 1970;168:1228-9 (new tab)PMID 5442709
- Lemberger L, Martz R, Rodda B, Forney R, Rowe H. Comparative pharmacology of Δ9-tetrahydrocannabinol and its metabolite, 11-OH-Δ9-tetrahydrocannabinol. J Clin Invest 1973;52:2411-7 (new tab)PMID 4729039
- Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 1972;177:62-4 (new tab)PMID 5041775
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804 (new tab)PMID 17712819
- Kumar AR, Patilea-Vrana GI, Anoshchenko O, Unadkat JD. Characterizing and quantifying extrahepatic metabolism of Δ9-THC and its psychoactive metabolite 11-OH-THC. Drug Metab Dispos 2022;50:734-740 (new tab)PMID 35370140
- Zagzoog A, Cabecinha A, Abramovici H, Laprairie RB. Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. Front Pharmacol 2022;13:956030 (new tab)PMID 36091813
- Järbe TU, McMillan DE. Δ9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl) 1980;71:281-9 (new tab)PMID 6256796
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
History
- Source
- No presence in the cannabis plant is documented. 11-OH-THC forms in the body as a phase I metabolite of Δ9-THC; it is also prepared in the laboratory as an analytical standard. Its share depends on the route of administration: about 10% of plasma THC concentrations after inhalation, concentrations close to those of THC after oral intake (Huestis 2007).
Metabolic pathway
No plant pathway: the molecule arises in the body through hydroxylation of the 11-methyl group of Δ9-THC, attributed mainly to hepatic CYP2C9 (Huestis 2007). The intestine also takes part in THC metabolism: in human intestinal microsomes, THC was depleted by CYP2C9 (fraction metabolised 0.89) and CYP3A (0.11) (Kumar et al. 2022). Further oxidation of 11-OH-THC leads to 11-nor-9-carboxy-Δ9-THC (THC-COOH), which is inactive.
Legal framework
- European Union
Not listed in the UN conventions, which cover Δ9-THC (Schedule II of the 1971 Convention) and six of its positional isomers (Schedule I); no European Union measure of its own was found. Checked 20/10/2026.
- France
Not named in the French narcotics list. It falls under the generic class of benzo[c]chromene derivatives, which allows a hydroxyalkyl function at position 9 (annex IV, ANSM decisions of 22 May and 3 June 2024). Its parent molecule, Δ9-THC, falls under the entry "Tetrahydrocannabinols, their esters, ethers, salts as well as the salts of the aforementioned derivatives", moved from annex IV to annex III by the ANSM decision of 6 February 2026. Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Metabolite
- Chemistry
C5 side chain · neutral form
- Parent molecule
Active metabolite.
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Nilsson IM, Agurell S, Nilsson JL, Ohlsson A, Sandberg F, Wahlqvist M. Delta-1-tetrahydrocannabinol: structure of a major metabolite. Science 1970;168:1228-9 (new tab)PMID 5442709
- Lemberger L, Martz R, Rodda B, Forney R, Rowe H. Comparative pharmacology of Δ9-tetrahydrocannabinol and its metabolite, 11-OH-Δ9-tetrahydrocannabinol. J Clin Invest 1973;52:2411-7 (new tab)PMID 4729039
- Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 1972;177:62-4 (new tab)PMID 5041775
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804 (new tab)PMID 17712819
- Kumar AR, Patilea-Vrana GI, Anoshchenko O, Unadkat JD. Characterizing and quantifying extrahepatic metabolism of Δ9-THC and its psychoactive metabolite 11-OH-THC. Drug Metab Dispos 2022;50:734-740 (new tab)PMID 35370140
- Zagzoog A, Cabecinha A, Abramovici H, Laprairie RB. Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. Front Pharmacol 2022;13:956030 (new tab)PMID 36091813
- Järbe TU, McMillan DE. Δ9-THC as a discriminative stimulus in rats and pigeons: generalization to THC metabolites and SP-111. Psychopharmacology (Berl) 1980;71:281-9 (new tab)PMID 6256796
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
Identifiers
Names
- Common name
- 11-Hydroxy-Δ9-tetrahydrocannabinol
- IUPAC name
- (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
- Other names
- 11-OH-THC · 11-hydroxy-THC · 11-OH-Δ9-THC · 7-OH-Δ1-THC
Identifiers
- Formula
- C₂₁H₃₀O₃
- CAS
- 36557-05-8
- PubChem CID
- 644022(new tab)
- ChEBI
- CHEBI:77270(new tab)
- InChIKey
- YCBKSSAWEUDACY-IAGOWNOFSA-N
- SMILES
- CCCCCC1=
CC2= C([C@@H] 3C= C(CC[C@H] 3C(O2) (C) C) CO) C(= C1) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.